Journal
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58
Volume 58, Issue -, Pages 411-428Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010617-052823
Keywords
mood disorders; major depressive disorder; inflammation; microbiome; therapeutics
Categories
Funding
- NCCIH NIH HHS [P50 AT008661] Funding Source: Medline
- NIMH NIH HHS [R01 MH104559, T32 MH087004, R01 MH090264] Funding Source: Medline
- National Center for Complementary & Integrative Health [P50AT008661] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH090264, T32MH087004, R01MH104559] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Mood disorders such as depression are among the most prevalent psychiatric disorders in the United States, but they are inadequately treated in a substantial proportion of patients. Accordingly, neuropsychiatric research has pivoted from investigation of monoaminergic mechanisms to exploration of novel mediators, including the role of inflammatory processes. Subsets of mood disorder patients exhibit immune-related abnormalities, including elevated levels of proinflammatory cytokines, monocytes, and neutrophils in the peripheral circulation; dysregulation of neuroglia and blood-brain barrier function; and disruption of gut microbiota. The field of psychoneuroimmunology is one of great therapeutic opportunity, yielding experimental therapeutics for mood disorders, such as peripheral cytokine targeting antibodies, microglia and astrocyte targeting therapies, and probiotic treatments for gut dysbiosis, and producing findings that identify therapeutic targets for future development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available